Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)EBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Zevra Therapeutics (ZVRA) Other Gross PP&E Adjustments (2018 - 2025)

Zevra Therapeutics' Other Gross PP&E Adjustments history spans 10 years, with the latest figure at -$6.8 million for Q4 2025.

  • For Q4 2025, Other Gross PP&E Adjustments fell 57.75% year-over-year to -$6.8 million; the TTM value through Dec 2025 reached -$6.8 million, down 57.75%, while the annual FY2025 figure was -$6.8 million, 57.75% down from the prior year.
  • Other Gross PP&E Adjustments reached -$6.8 million in Q4 2025 per ZVRA's latest filing, down from -$1.7 million in the prior quarter.
  • In the past five years, Other Gross PP&E Adjustments ranged from a high of $1.4 million in Q4 2021 to a low of -$7.3 million in Q3 2024.
  • Average Other Gross PP&E Adjustments over 5 years is -$2.5 million, with a median of -$1.2 million recorded in 2021.
  • Peak YoY movement for Other Gross PP&E Adjustments: skyrocketed 729.02% in 2021, then tumbled 948.71% in 2024.
  • A 5-year view of Other Gross PP&E Adjustments shows it stood at $1.4 million in 2021, then plummeted by 32.58% to $950000.0 in 2022, then plummeted by 30.11% to $664000.0 in 2023, then plummeted by 745.48% to -$4.3 million in 2024, then plummeted by 57.75% to -$6.8 million in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's Other Gross PP&E Adjustments are -$6.8 million (Q4 2025), -$1.7 million (Q3 2025), and -$2.1 million (Q2 2025).